Home Cart Sign in  
Chemical Structure| 1435-55-8 Chemical Structure| 1435-55-8

Structure of (+)-Dihydroquinidine
CAS No.: 1435-55-8

Chemical Structure| 1435-55-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hydroquinidine is a cinchona alkaloid, used as an antiarrhythmic agent to decrease heart rate variability.

Synonyms: (+)-Hydroquinidine; Hydroconquinine; Dihydroquinidine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (+)-Dihydroquinidine

CAS No. :1435-55-8
Formula : C20H26N2O2
M.W : 326.43
SMILES Code : [C@H](O)(C=1C2=C(C=CC(OC)=C2)N=CC1)[C@@]3([N@@]4C[C@H](CC)[C@H](C3)CC4)[H]
Synonyms :
(+)-Hydroquinidine; Hydroconquinine; Dihydroquinidine
MDL No. :MFCD00135599

Safety of (+)-Dihydroquinidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H332
Precautionary Statements:P280

Isoform Comparison

Biological Activity

Description
Hydroquinidine, a derivative of the antiarrhythmic agent Quinidine, extends the QT interval and demonstrates antiarrhythmic properties[1].[2].[3].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00789165 Arrhythmia Phase 2 Phase 3 Recruiting - United States, Pennsylvania ... More >> Lankenau Institute for Medical Research Not yet recruiting Wynnewood, Pennsylvania, United States, 19096 Contact: Charles Antzelevitch, PhD, FACC, FAHA, FHRS    (315) 725-1390    cantzelevitch@gmaill.com    Principal Investigator: Charles Antzelevitch, PhD, FACC, FAHA, FHRS          Germany University Medical Centre Mannheim Recruiting Mannheim, Germany Contact: Boris Rudic, MD       boris.rudic@umm.de    Principal Investigator: Boris Rudic, MD          Israel Tel Aviv Medical Center Recruiting Tel Aviv, Israel, 64239 Contact: Sami Viskin, M.D.    972524266859    saviskin@tasmc.health.gov.il    Sub-Investigator: Bernard Belhassen, M.D.          Italy University of Pavia and IRCCS Fondazione Policlinico San Matteo Recruiting Pavia, Italy Contact: Lia Crotti, MD PhD       l.crotti@smatteo.pv.it    Sub-Investigator: Lia Crotti, MD PhD          Principal Investigator: Peter J Schwartz, MD          Japan National Cardiovascular Center Recruiting Osaka, Japan Contact: Wataru Shimizu, M.D.       :wshimizu@hsp.ncvc.go.jp    Principal Investigator: Wataru Shimizu, M.D.          Netherlands Academic Medical Centre Recruiting Amsterdam, Netherlands Contact: Arthur AM Wilde, M.D.       a.a.wilde@amc.uva.nl    Sub-Investigator: Hanno L. Tan, M.D. PhD          Principal Investigator: Arthur AM Wilde, MD PhD Less <<
NCT00927732 Brugada Syndrome Phase 3 Terminated(insufficient recrui... More >>tment, a lot of premature study discontinuations) Less << - France ... More >> CHU Amiens Amiens, France, 80 CHU Angers Angers, France, 49 CHU Bordeaux Bordeaux, France, 33 CHU Brest Brest, France, 29 CHU Grenoble Grenoble, France, 38 CHRU Lille Lille, France, 59 CHU Lyon Lyon, France, 69 AP-HM Marseille Marseille, France, 13 CHU Montpellier Montpellier, France, 34 CHU Nancy Nancy, France, 54 CHU Nantes Nantes, France, 44093 AP-HP Paris Lariboisière Paris, France, 75 CHU Poitiers Poitiers, France, 86 CHU Rennes Rennes, France, 35 CHU Strasbourg Strasbourg, France, 67 CHU Toulouse Toulouse, France, 31 CHU Tours Tours, France, 37 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.06mL

0.61mL

0.31mL

15.32mL

3.06mL

1.53mL

30.63mL

6.13mL

3.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories